Prognostic Impact of Relative Dose Intensity of Adjuvant Chemotherapy With S-1 on Pancreatic Ductal Adenocarcinoma

Matsushima, Hajime; Adachi, Tomohiko; HIDAKA, MASAAKI; YAMASHITA, MAMPEI; Hamada, Takashi; Fukui, Saeko; Tanaka, Takayuki; Imamura, Hajime; Yoshino, Kyohei; Kugiyama, Tota; KITASATO, Amane; Hara, Takanobu; Soyama, Akihiko; Kobayashi, Kazuma; Sumida, Yorihisa; Kuroki, Tamotsu; EGUCHI, Susumu

doi:10.21873/anticanres.15802

Cited by 7 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another colon cancer study, RDI was associated with outcome in patients with a high risk of recurrence but not in those with a low recurrence risk; furthermore, maintaining an RDI of 60-70% or greater was associated with better prognosis [12]. In patients with pancreatic ductal adenocarcinoma, an RDI of 72.3% or higher was associated with better overall survival after resection [20]. Maintaining an NAC RDI of ≥85% contributes to improved overall survival in patients with human epidermal growth factor receptor 2-negative breast cancer [21].…”

Section: Discussionmentioning

confidence: 93%

Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients

Shiraishi¹,

Katô²,

Momose³

et al. 2023

Oncology

View full text Add to dashboard Cite

Introduction. This study aimed to clarify the impact of the average relative dose intensity (RDI) of neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-NAC) for resectable locally advanced esophageal squamous cell carcinoma (ESCC). Materials and Methods. To identify the optimal RDI, recurrence-free survival (RFS) and cumulative incidence function for recurrence (CIF) were calculated in low and high RDI groups with any cut-off points. The optimal RDI was defined as the highest RDI administered with a significant increase in either RFS or CIF. The clinicopathological characteristics of the two groups divided by optimal RDI were investigated. The preoperative prognostic factors associated with RFS were confirmed by multivariable Cox proportional hazards model. Results. Among the 150 eligible patients treated with DCF-NAC from 2010 to 2020, 3-year RFS and CIF were 56.3% and 37.8% in 90 patients in the less than 80% RDI group (<80% RDI), and 73.3% and 26.7% in 60 patients in the more than or equal to 80% RDI group (≥80% RDI), respectively. The optimal cut-off RDI was identified as 80%. The <80% RDI group included older individuals, a lower value of creatinine clearance, a higher Charlson Comorbidity Index, reduced RDI at first course, and grade 1–0 in the histopathological tumor response than the ≥80% RDI group. R0 resection and postoperative complication rates were equal in both groups. Cox proportional hazards model identified the response rate and RDI as predictors of recurrence free survival. Conclusion. An average RDI of more than or equal to 80% improved prognosis in patients receiving DCF-NAC for ESCC.

show abstract

Section: Discussionmentioning

confidence: 93%

Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients

Shiraishi¹,

Katô²,

Momose³

et al. 2023

Oncology

View full text Add to dashboard Cite

show abstract

“…Only a few studies have reported on the important impact on survival of both completion of planned postoperative adjuvant chemotherapy and of dose intensity after surgery for PADC. [16][17][18] Kobayashi et al found an association between a low total dose intensity of adjuvant S-1 chemotherapy and a poorer prognosis in patients who had undergone pancreatectomy for pancreatic cancer. [18] However, their cohort included approximately 30% of patients with invasive IPMC and also included patients having developed early recurrences during administration of adjuvant S-1 chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival after resection of pancreatic ductal adenocarcinoma: A retrospective study

Sakamoto,

Kishino,

Murakami

et al. 2024

Medicine

View full text Add to dashboard Cite

This study aimed to investigate the prognostic relationship between relative dose intensity (RDI) of adjuvant S-1 chemotherapy and psoas muscle mass volume (PMV) in patients with resected pancreatic ductal adenocarcinoma. We enrolled 105 patients with histologically confirmed pancreatic ductal adenocarcinoma who had undergone pancreatectomy. Adjuvant S-1 chemotherapy was administered to 72 (68.6%) of the 105 patients and not to the remaining 33 patients. Patients who received adjuvant S-1 chemotherapy were stratified into high- and low-RDI groups by the cutoff value for RDI. Five-year overall survival (OS) and relapse-free survival (RFS) rates were significantly higher in the high- than in the low-RDI group. Similarly, both the 5-year OS and RFS rates were significantly greater among patients in the high-PMV group than among patients in the low-PMV group. The RDI was an independent prognostic factor in our study patients. Furthermore, patients who received adjuvant S-1 chemotherapy were stratified into 3 groups: those with both high RDI and high-PMV, Group A; those with either high RDI or high PMV (but not both), Group B; and those with both low RDI and low-PMV, group C. There were statistically significant differences in 5-year OS and RFS between 3 patient groups (5-year overall survival: P = .023, 5-year relapse-free survival: P = .001). The area under the curve for the combination of RDI and PMV (0.674) was greater than that for RDI alone (0.645). A sufficient dosage of adjuvant S-1 chemotherapy is important in improving survival of patients with resected pancreatic ductal adenocarcinoma. A combination of RDI and PMV may predict the prognosis of patients with resected pancreatic ductal adenocarcinoma more effective than RDI alone.

show abstract

“…Additionally, the survival of patients in cases where the dosage of S-1 was reduced and in those where it was not reduced was not evaluated. Only a few studies have reported on the important impact on survival of both completion of planned postoperative adjuvant chemotherapy and of dose intensity after surgery for PADC [16][17][18]. Kobayashi et al found an association between a low total dose intensity of adjuvant S-1 chemotherapy and a poorer prognosis in patients who had undergone pancreatectomy for pancreatic cancer [18].…”

Section: Discussionmentioning

confidence: 99%

Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival after resection of pancreatic ductal adenocarcinoma

Sakamoto,

Murakami,

Hanaki

et al. 2024

HPB

View full text Add to dashboard Cite

Prognostic Impact of Relative Dose Intensity of Adjuvant Chemotherapy With S-1 on Pancreatic Ductal Adenocarcinoma

Cited by 7 publications

References 0 publications

Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients

Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients

Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival after resection of pancreatic ductal adenocarcinoma: A retrospective study

Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival after resection of pancreatic ductal adenocarcinoma

Contact Info

Product

Resources

About